Founder GP at 3CC | Third Culture Capital, Healthcare VC Boston, a venture capital firm that invests in “uniquely qualified” founders, through global agency and smart capital. He has over 30 years of leadership experience in clinical settings and in emerging medical innovation companies.
Julien is a nephrologist, serial founder/entrepreneur, and investor interested in innovation and the impact of disruptive thinking and technology in the practice and delivery of modern Medicine. Most recently, I was the President & Chief Operating Officer of a publicly traded clinical-stage biotech developing "21st Century Gene Therapy for Cancer" (NASDAQ: GNPX). Genprex’s technology and unique approach involves the systemic delivery of a tumor suppressor gene/DNA plasmid construct, encapsulated in an optimized lipid nanovesicle. The company is readying to enter phase I/II clinical trials in Non-Small Lung Cell Cancer. Previous startup and academic experience include: - RubiconMD. Prior to RubiconMD, he served on faculty at Harvard Medical School’s Brigham and Women’s Hospital with an appointment at Dana Farber Cancer Institute. He received his MD from the University of Washington School of Medicine and his MPH at the Harvard School of Public health.